Highlights Healios K.K.

Equities

4593

JP3835100003

Market Closed - Japan Exchange Other stock markets 11:30:00 17/05/2024 am IST			5-day change	1st Jan Change
144 ^JPY	+0.70%		-7.10%	-12.73%

10/04	Healios Partners with AND Medical Group; Set to Receive Upfront Payment of 60 Million Yen	MT
09/04	Healios K.K. Enters into Joint Research Agreement with AND Medical Group	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Healios Partners with AND Medical Group; Set to Receive Upfront Payment of 60 Million Yen	10/04	MT
Healios K.K. Enters into Joint Research Agreement with AND Medical Group	09/04	CI
Healios Concludes Purchase of Athersys Assets, Becoming Sole Owner of MultiStem IP	04/04	MT
Healios K.K. completed the acquisition of Substantially all assets of Abt Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC .	03/04	CI
Healios K.K. and ProcellCure Inc. Announce Start of ARDS Clinical Trial in Japan	02/02	CI
Healios K.K. and Its Wholly Owned Subsidiary ProcellCure Inc. Announce Submission of ARDS Clinical Trial Notification in Japan	18/01	CI
Healios Secures LOI on Joint Research with AND	17/01	MT
Healios K.K. AND Medical Group Enter into A Letter of Intent for A Basic Agreement for Joint Research	16/01	CI
Healios Steps In as Primary Bidder and Lender for Athersys’s Asset Sale Amidst Bankruptcy	10/01	MT
Healios K.K. entered into an asset purchase agreement to acquire Substantially all assets of ABT Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC for $2.8 million.	05/01	CI
Healios, Nobelpharma in Talks for Stem Cell Therapy Alliance for ARDS	28/12	MT
Healios Invests in Arktus Therapeutics at Undisclosed Amount	26/12	MT
Healios K.K. (TSE : 4593) agreed to acquire an unknown minority stake in Arktus Therapeutics Co., Ltd.	22/12	CI
California Institute for Regenerative Medicine Awards $1 Million from the California Institute for Regenerative Medicine for Healios' Hypo-immune UDC	30/23/30	CI
Healios Secures Exclusive License for Cell Therapy Drug, Expanding Treatment for Acute Respiratory Distress Syndrome	11/23/11	MT
HEALIOS K.K. Conducts the Treasure Study to Investigate the Safety and Efficacy of HLCM051	11/23/11	CI
HEALIO K.K. Provides its Innovative eNK Platform for A Novel Research Study on Metastatic Uveal Melanoma At Thomas Jefferson University in Philadelphia	14/23/14	CI
Healios K.K. Establish Subsidiary to Promote the Development	14/23/14	CI
Healios and Saisei Ventures Enter into a Letter of Intent for eNK Research and Development	11/23/11	CI
Healios Announces Establish Subsidiary for ENK Research and Development	11/23/11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Healios K.K.

Equities

4593

JP3835100003

Highlights

Filters